Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07724951) titled 'The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study' on July 21.

Study Type: Observational

Primary Sponsor: Shanghai Zhongshan Hospital

Condition: Hepatocellular Carcinoma (HCC)

Intervention: Drug: Donafeinib Procedure: Transcatheter arterial chemoembolization Drug: PD-1 / PD-L1 monoclonal antibody

Recruitment Status: Not recruiting

Date of First Enrollment: July 31, 2026

Target Sample Size: 400

Countries of Recruitment: China

To know more, visit https://clini...